IRVING, Texas and PHOENIX, Oct. 1, 2009 (GLOBE NEWSWIRE) -- Caris Diagnostics ("Caris Dx"), a leading provider of integrated anatomic pathology and oncology testing services including molecular profiling and hematopathology, today announced the appointment of Chris Roberts as Vice President of the Target Now franchise. In this new role, Chris will meet the growing needs associated with Caris' expanding molecular business.
"I'm very excited to be part of Caris Diagnostics and look forward to growing the molecular profiling business," said Chris Roberts. "Every patient is unique, and so is their cancer. Caris is delivering on the promise of personalized medicine by providing the right information at the right time so oncologists can make the best treatment decisions for their patients."
Chris brings deep knowledge and a wealth of experience to his new role, including engineering, production, strategic marketing, and project management expertise. His background also includes working closely with diagnostic manufacturers in the development of point-of-care rapid immunodiagnostic test kits. Prior to joining Caris, Chris worked for Ventana Medical Systems, where he launched over 20 new diagnostic test kits and established a global key opinion leader network. Chris' work at Caris will focus exclusively on the growing Target Now portfolio, including all aspects of commercial execution.
"Our rapidly growing Target Now molecular profiling franchise requires the type of strong commercial leadership that Chris' deep experience and expertise in molecular diagnostics provides," commented Mike Guidotti, Senior Vice President, Caris Oncology. "We are very pleased that Chris chose to join the Caris organization in its exciting quest to accelerate the advancement of personalized medicine and targeted therapeutics for cancer patients."
About Caris Diagnostics
Caris Dx is a U.S.-based biosciences company specializing in the development and commercialization of clinically-validated molecular diagnostics and anatomic pathology services primarily in the fields of oncology, dermatopathology, hematopathology and gastrointestinal pathology. The company provides academic-caliber medical consults through its industry-leading team of subspecialty fellowships and expert-trained pathologists in gastrointestinal and liver pathology, dermatopathology and hematopathology. Caris Dx also offers advanced molecular analyses of patient samples through prognostic testing services and genomic and proteomic profiling to assist physicians in their treatment of cancer and other complex diseases. Currently, Caris Dx receives and analyzes biopsies for more than 2,700 patients per day, referred by more than 2,500 physicians nationally. Formed in 1996, the company is headquartered in Irving, Texas and operates four laboratories: Irving, Texas; Phoenix, Arizona (2 sites) and Newton, Massachusetts. Additional information is available at www.carisdx.com.